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INTRODUCTION 
Hepatocyte growth factor (HGF) is a multifunctional cytokine with important 
roles in cell proliferation, survival, motility and morphogenesis. Secreted by cells of 
mesenchymal origin, HGF is the specific ligand for the tyrosine-kinase receptor c-
MET (cellular mesenchymal-epithelial transition), also called MET, which is 
expressed in different types of epithelial, endothelial and haematopoietic progenitor 
cells. The HGF/MET axis is involved in several biological processes, such as 
embryogenesis, organogenesis, adult tissue regeneration (including wound healing 
and liver regeneration) and carcinogenesis, for both solid and haematological 
malignancies.[1 2] HGF and its particular interaction with the MET receptor have 
been extensively investigated in the last decades and remain the focus of numerous 
clinical trials.[3-8] This short review focuses on HGF structure and function, as well 
as its roles in liver regeneration and different types of tumour. 
 
HGF STRUCTURE 
HGF is mapped on the long arm of chromosome 7 at q21.1 and it is formed 
by 18 exons, interrupted by 17 introns, spanning 71,433 bases of genomic DNA. It 
encodes the inactive pre-pro-HGF, a single chain of 728 amino acids (83134 Da), 
which includes a signal sequence (1-31), a heavy alpha-chain (32-494; 69kDa) and a 
light beta-chain (495-728; 34kDa). The first exon contains the signal peptide and a 5'-
untranslated region. The following ten, twelve and six remaining exons encode the 
alpha-chain, with four kringle structures, the short spacer region between the alpha- 
and beta-chains and the beta-chain, respectively.[9-11] HGF primary structure was 
determined in 1989, but multiple transcript variants encoding different isoforms have 
been identified by alternative splicing of the gene since then.[12] 
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The inactive pre-pro-HGF becomes active after a two-cleavage process. 
Firstly, the signal peptide of the pre-pro-HGF is degraded, generating the pro-HGF, 
which is also cleaved between Arg494 and Val495. Several serum or cell-membrane 
proteases have been described to be involved, such as HGF activator (HGF-A), 
urokinase-type plasminogen activator, plasma kallikrein, coagulation factors XII and 
XI, matriptase and hepsin.[13]  
Among them, HGF-A is the main protease responsible for the activation of 
pro-HGF in serum. The activation process of HGF plays an important role in the 
regulation of tissue regeneration and susceptibility to pathological conditions. 
Although HGF-A knock-out mice showed normal development, they have impaired 
restitution of epithelia after mucosal injury.[14] Similarly, fibroblasts from patients with 
idiopathic pulmonary fibrosis have been shown to have lower capacity to activate 
HGF compared with control fibroblasts.[15]  
The final active heterodimeric molecule is produced by a disulphide bond 
between the alpha and beta chains. Although this multifunctional protein belongs to 
the plasminogen subfamily of S1 peptidases, no proteolytic activity has been 
detected, probably due to the substitution of two out of three amino acids required in 
the catalytic triad.[16] It has been suggested that HGF could be evolutionally derived 
from those encoding proteases implicated in the coagulation cascade and 
fibrinolysis. Indeed, not only is its organisation very similar, but its products are also. 
The HGF alpha-chain has 38% homology with plasmin, and the beta-chain is 
structurally similar to the catalytic domains of serine proteases, but with amino acid 
substitutions in the active site.[1]  
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In contrast to other growth factors and their receptors, HGF binds exclusively 
to the product of the c-MET proto-oncogene, also mapped on chromosome 7.[17-19] 
The MET receptor is a 190kDa protein, comprising a ligand-binding extracellular 
domain, a transmembrane region and a cytoplasmic domain with tyrosine kinase 
activity. Although HGF alfa-chain has a higher affinity for MET, it is the beta-chain 
which activates the receptor.[20 21] Upon MET dimerization, kinase activation results 
in auto-phosphorylation of tyrosines Y1349 and Y1356, and recruitment of several 
substrates, including growth factor receptor-bound protein 2, Shc, p85 subunit of 
phosphatidylinositol 3' kinase, phospholipase C γ, signal transducer and activator of 
transcription 3 (STAT3) and Grb2-associated binding protein 1. The downstream 
signalling pathways generate diverse cellular responses, such as proliferation, 
survival, motility, invasion and stimulation of angiogenesis (Figure 1).[22-34]  
Several growth factors, cytokines and prostaglandins upregulate HGF gene 
expression: b-FGF (basic fibroblast growth factor), OSM (oncostatin M), HIF-1α 
(hypoxia-inducible factor 1 alfa) and NF-κB (nuclear factor kappa B). Its main 
inhibitor is TGF-β (tumour growth factor beta).[35] 
 
HGF FUNCTION AND ITS RECEPTOR 
 
In 1984, HGF was purified for the first time in rat platelets, and 4 years later in 
humans. It was described as a potent mitogenic factor for mature rat hepatocytes in 
vitro.[36-39] The HGF/MET pathway has diverse biological and physiological roles in 
organogenesis, morphogenesis, tissue regeneration and carcinogenesis that have 
been discovered using conditional knockout of MET in mice.[8] In 1991, a fibroblast-
derived factor for epithelial cells, the Scatter factor (SF), involved in increasing cell 
migration during embryogenesis and tumour progression, together with the human 
lung fibroblast-derived mitogen, were found to be identical proteins. Both are 
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encoded by the same chromosome bands as the HGF and are ligands for MET 
receptor.[40-44] Soon after, a tumour cytotoxic factor derived from fibroblasts, which 
induces cell death in several cancer types, was also found to be an identical 
molecule to HGF.[45] These results had important consequences for further studies 
on the involvement of HGF as a modulator of cellular growth and motility during 
embryogenesis, tissue regeneration and carcinogenesis. Interestingly, targeted 
disruption of HGF or MET results in embryonically lethal knockouts with impaired 
development of the liver and placenta.[46 47] Over-expression, mutations, and 
amplification of the receptor and/or changes in its kinase activity have been 
implicated in different types of cancer.[48] 
It has been suggested that because of the proximity between HGF and MET 
on chromosome 7, a polysomy of this chromosome could lead to malignancy 
secondary to overproduction of both molecules.[49] The one-to-one ligand-receptor 
relationship makes the HGF/MET axis an attractive target for drug development, 
either by activation or inhibition of this pathway. Three pharmacologic approaches 
are currently being developed as inhibitors of MET signalling with promising results: 
anti-HGF antibodies, anti-MET antibodies and MET kinase inhibitors.[50] 
 
HGF AND LIVER REGENERATION 
 
The liver has the ability to regenerate to almost its optimal volume after liver 
resection.[51] HGF is one of two complete mitogens which induce hepatocyte DNA 
synthesis and mitosis along with EGFR. Activation of the HGF/MET axis generates a 
cascade of intracellular signalling for the G1-S progression of hepatocytes. Available 
evidence has shown that immediately after different liver injuries, such as partial 
hepatectomy, ischaemia or hepatitis, there is an intense remodelling of the 
extracellular matrix, with increased activity of proteinases and intense intracellular 
signalling.[52] The levels of active HGF rise rapidly in the liver secondary to its 
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production by Kupffer, stellate and sinusoidal endothelial cells, and subsequently 
activation by urokinases.[53-55] Since HGF also increases in plasma, an endocrine 
mechanism has been suggested. In addition, HGF mRNA and HGF activity have 
been found to be markedly higher in other intact organs like the lung, kidney or 
spleen after injuries of the liver.[56] Overall, this results in a balanced liver growth 
and regeneration. 
 
HGF AND HEPATOCELLULAR CARCINOMA 
Hepatocellular carcinoma (HCC) is the 3rd most common cause of cancer-
related mortality worldwide with a multifactorial aetiology and extensive molecular 
and phenotypic heterogeneity.[57] Several signalling pathways have been described 
in which the HGF/MET axis may play a crucial role.[58-60] Patients with HCC have 
significantly higher serum levels of HGF compared to healthy controls [52 61] and 
over-expression of HGF and c-MET has been detected in 33% and 20-48% of HCC 
tissues, respectively.[62-66] Up-regulation of MET has also been associated with 
tumour migration, vascular invasion, neo-angiogenesis and, therefore, poor patient 
outcomes.[67] In contrast, other studies have shown contradictory results with 
regards to their impact on survival in HCC patients.[68-73] Nonetheless, clinical trials 
using pharmacological inhibitors of this axis for both HCC and other solid 
malignancies are currently being performed. These targeted therapies could be a 
promising second line option to treat patients with advanced HCC.[60 74 75] A recent 
study has demonstrated that the mixed-lineage leukaemia (MLL) protein, in 
association with HGF/MET, promotes cell invasion and metastasis in HCC. 
Theoretically, the inhibition of this interaction could potentially reduce the incidence 
of distant metastasis, although it may not affect the tumour load or its proliferative 
capacity.[76] 
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HGF IN OESOPHAGO-GASTRIC CANCER 
Oesophago-gastric cancer (OGC) is the 5th most common malignancy 
worldwide and the 4th and 5th most common type of cancer death in males & 
females in UK, respectively. A clear geographical difference has been observed in 
overall-survival with 70% surviving 5 years in Japan, compared to 25% in Europe, 
suggesting that the implementation of screening tools might allow earlier detection 
and treatment of this cancer. OGC have a diverse molecular landscape and exhibit 
alterations in various different oncogenes and kinase pathways. Activation of the 
HGF/MET axis promoting tumourigenesis and metastasis in gastric cancer is mainly 
secondary to MET over-expression and/or amplification, which was observed in 75–
90% of cases and in 1.5–20% of the patients, respectively.[77-79] However, 
mutations of HGF or MET are extremely rare in OGC.[80 81] Different drugs 
targeting the axis include tyrosine kinase inhibitors (crizotinib, a dual c-MET and ALK 
inhibitor), and monoclonal antibodies that neutralise HGF (Rilotumumab) or MET 
(Onartuzumab) are currently being trialled.[82-86] 
 
HGF IN COLORECTAL CANCER 
Colorectal cancer is the 3rd most common cancer in men and the 2nd in 
women worldwide,[87] and around 30% of the patients will develop metastasis even 
after curative surgery. It has been suggested that the HGF/MET axis is involved in 
the metastatic progression and potential invasiveness of the cancer cells by 
regulating the expression of cadherins and extracellular membrane proteases.[88] 
Besides, MET amplification seems to be a late event in CRC progression. MET 
amplification is more common in advanced tumour stages [89] and its expression has 
been found to be higher in  metastatic tissue than primary tumour.[90] 
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Although survival of patients with unresectable metastatic CRC (mCRC) has 
improved in the last years with the introduction of agents targeting the epidermal 
growth factor receptor (EGFR), such as cetuximab, its response rate range varies 
from 10-20%.[91 92] HGF-induced MET activation has been described as a novel 
mechanism for cetuximab resistance. Dual activation of both EGFR and MET 
receptors in CRC cells synergistically increases cell proliferation [93]. Cetuximab 
could inhibit this cell growth by 60-80%. However, addition of HGF to cetuximab-
treated cells phosphorylated MET, but not EGFR, restoring cell proliferation. 
Inhibition of the HGF/MET axis may therefore improve response to EGFR inhibitors 
in CRC, and combination therapy should be further investigated.[93] A recent study 
revealed that high levels of serum HGF and epiregulin (EREG) before treatment with 
anti-EGFR antibodies were associated with poor survival in KRAS wild-type patients 
with mCRC, suggesting that serum HGF and EREG may be associated with 
resistance to anti-EGFR treatment. HGF might be a potential biomarker for predicting 
response and prognosis in dual target therapy with anti-EGFR antibodies and 
HGF/MET inhibitors.[94]  
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TAKE HOME POINTS 
• HGF is a multi-functional cytokine produced by cells of mesenchymal origin 
involved in cell proliferation, survival, motility and morphogenesis. 
• MET is a tyrosine kinase receptor physiologically expressed on cells of 
epithelial origin and HGF is its unique binding factor. 
• HGF/MET axis plays important roles in embryogenesis, organogenesis, adult 
tissue regeneration and carcinogenesis. 
• Both HGF and MET genes can be over-expressed, potentially mutated, 
and/or amplified in several types of cancers, including haematological 
malignancies. 
• HGF/MET axis has become the candidate target of numerous therapeutic 
clinical trials. 
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FIGURE LEGEND 
Figure 1. The HGF/MET axis. Once HGF is activated by a two-cleavage process in 
the extracellular matrix, it binds to the MET receptor on epithelial cells, promoting its 
dimerization and auto-phosphorylation of tyrosine residues. The recruitment of 
adaptor proteins generates different downstream signalling pathways which evoke 
diverse cellular responses as shown. Key: C-Cbl: Casitas B-lineage Lymphoma; 
Erk1-2: extracellular-signal-regulated kinases; FAK: focal adhesion kinase; GAB1: 
Grb2-associated binding protein 1; Grb2: growth factor receptor bound protein 2; 
Gsk3β: glycogen synthetase kinase 3β; IKK: inhibitor of nuclear factor kappa-B 
kinase; MEK, mitogen-activated protein kinase/ERK kinase; mTOR: mammalian 
target of rapamycin; NF-kβ: nuclear factor kappa-B;; PI3K: phosphatidylinositol 3' 
kinase; PLCγ: phospholipase C-γ;Stat3: signal transducer and activator of 
transcription 3. Adapted from [35].  
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Figure 1. The HGF/MET axis. Once HGF is activated by a two-cleavage process in the extracellular matrix, it 
binds to the MET receptor on epithelial cells, promoting its dimerization and auto-phosphorylation of tyrosine 
residues. The recruitment of adaptor proteins generates different downstream signalling pathways which 
evoke diverse cellular responses as shown. Key: C-Cbl: Casitas B-lineage Lymphoma; Erk1-2: extracellular-
signal-regulated kinases; FAK: focal adhesion kinase; GAB1: Grb2-associated binding protein 1; Grb2: 
growth factor receptor bound protein 2; Gsk3β: glycogen synthetase kinase 3β; IKK: inhibitor of nuclear 
factor kappa-B kinase; MEK, mitogen-activated protein kinase/ERK kinase; mTOR: mammalian target of 
rapamycin; NF-kβ: nuclear factor kappa-B;; PI3K: phosphatidylinositol 3' kinase; PLCγ: phospholipase C-
γ;Stat3: signal transducer and activator of transcription 3. Adapted from [35].  
134x101mm (300 x 300 DPI)  
 
 
Page 18 of 18
https://mc.manuscriptcentral.com/jclinpathol
Journal of Clinical Pathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
